Business Wire

ADVA sync solution enables major Chilean telco to roll out 5G-ready network

28.10.2019 15:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that its Oscilloquartz synchronization technology is enabling one of Chile’s largest communication service providers (CSPs) to roll out LTE Advanced (LTE-A) connectivity across the country and prepare for 5G. The OSA 5430 Series and OSA 5410 Series of PTP grandmaster clocks and GNSS receivers deliver stringent phase synchronization in the core and in the access network, enabling the company to address rapidly rising customer demand for premium services such as high-definition video streaming. The deployment strengthens ADVA’s position in the market with its timing technology now synchronizing more of Chile’s major CSP networks than any other supplier’s solutions. The network is being installed by ADVA’s long-term partner Sistemas de Instrumentación Ltda.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005386/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The OSA 5430 Series and OSA 5410 Series are enabling one of Chile’s largest CSPs to roll out national LTE-A connectivity (Photo: Business Wire)

“Being selected to transform the sync network of another of Chile’s key CSPs highlights the unique benefits of our grandmaster clocks and GNSS receiver portfolio. With high-quality oscillators guaranteeing unbeatable holdover and the continual assurance of in-service sync with our built-in probes, our technology offers the most complete and comprehensive solution for advanced timing in telecom networks. It will generate value for years to come,” said Gil Biran, general manager, Oscilloquartz. “Our mission is to provide exceptional service to all of our customers. With our technology and ongoing support, we’re empowering another major company to reshape Chile’s telecommunication landscape, reaching more people than ever while continuing to deliver unrivalled quality of service.”

By deploying the small yet versatile OSA 5410 Series in the access networks, the CSP is providing advanced, time-sensitive mobile connectivity throughout Chile, including previously underserved regions. At once a mini-grandmaster, boundary clock, slave device and sync probe, ADVA’s multipurpose devices lead the industry in terms of adaptability and innovation. At its core, the company is utilizing the OSA 5430 Series, which offers full hardware redundancy, significantly reducing downtime. This high-capacity unit also provides unprecedented scale, supporting speeds of up to 10Gbit/s. Additionally, the OSA 5410 and 5430 both support assisted partial timing support (APTS) and feature Oscilloquartz’s best-in-class oven-controlled crystal oscillators, which offer exceptional holdover performance even in the most challenging conditions.

"We work closely with our partner ADVA to deliver world-class technology that ensures unbeatable quality and availability. Their Oscilloquartz grandmasters are the most advanced timing solutions on the market. Ideal for distributing ultra-precise, incredibly reliable phase and time-of-day information, these devices are now providing the heartbeat of another of Chile’s leading CSPs,” commented Danor Quinteros, CEO, Sistemas de Instrumentación Ltda. “One of the crucial elements of this deployment was bringing synchronization close to the end user where it’s most needed. The compact and feature-rich OSA 5410 devices in the access network and the high-capacity OSA 5430 in the core infrastructure will be key to delivering ever-faster speeds and latency-sensitive applications.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com.

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to- end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA Optical Networking company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at: www.oscilloquartz.com.

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye